fig2

Figure 2. LSC-specific surface markers and the different types of drug agents targeting these markers. All depicted surface markers except CD19 are differentially expressed on AML LSCs. CD19 is a marker specific for B-ALL blasts. In addition, CD7 and CD25 have also been used as targets for ALL treatment. The depicted agents have recently been used in clinical trials. Created with BioRender.com. LSC: Leukemic stem cell; AML: acute myeloid leukemia; CAR: chimeric antigen receptor; TDB: T cell-dependent bispecific; DART: dual-affinity re-targeting antibody.